Fmr LLC Acquires 37,489 Shares of Regulus Therapeutics Inc. (RGLS)
Fmr LLC grew its holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) by 0.5% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,977,349 shares of the biopharmaceutical company’s stock after purchasing an additional 37,489 shares during the quarter. Fmr LLC owned approximately 15.00% of Regulus Therapeutics worth $7,862,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of the company. Wedbush Securities Inc. raised its holdings in shares of Regulus Therapeutics by 10.3% in the 2nd quarter. Wedbush Securities Inc. now owns 199,521 shares of the biopharmaceutical company’s stock valued at $197,000 after purchasing an additional 18,600 shares in the last quarter. Tudor Investment Corp ET AL raised its holdings in shares of Regulus Therapeutics by 131.5% in the 1st quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 61,373 shares in the last quarter. Quantitative Investment Management LLC bought a new stake in shares of Regulus Therapeutics in the 2nd quarter valued at about $103,000. GSA Capital Partners LLP bought a new stake in shares of Regulus Therapeutics in the 2nd quarter valued at about $139,000. Finally, LMR Partners LLP bought a new stake in shares of Regulus Therapeutics in the 2nd quarter valued at about $164,000. Institutional investors and hedge funds own 21.97% of the company’s stock.
Regulus Therapeutics (NASDAQ:RGLS) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million. Regulus Therapeutics had a negative net margin of 31,460.47% and a negative return on equity of 173.20%.
TRADEMARK VIOLATION NOTICE: This article was first posted by Daily Political and is the property of of Daily Political. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.dailypolitical.com/2017/11/02/fmr-llc-acquires-37489-shares-of-regulus-therapeutics-inc-rgls.html.
Several equities research analysts have recently commented on RGLS shares. Zacks Investment Research upgraded shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a report on Saturday, September 16th. Wedbush restated an “ourperform” rating and issued a $4.00 price target on shares of Regulus Therapeutics in a report on Monday, August 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Regulus Therapeutics in a research report on Wednesday, August 2nd. Finally, Chardan Capital downgraded shares of Regulus Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 2nd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $3.67.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Want to see what other hedge funds are holding RGLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regulus Therapeutics Inc. (NASDAQ:RGLS).
Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.